Literature DB >> 1532014

The development and testing of an instrument to measure self-efficacy in individuals with epilepsy.

C Dilorio1, B Faherty, B Manteuffel.   

Abstract

The purpose of this study was to develop and test an instrument to measure self-efficacy in persons with epilepsy. With Bandura's self-efficacy theory serving as the conceptual basis for instrument development, the study was divided into two phases, an instrument development phase and a reliability and validity assessment phase. In phase one, self-efficacy and epilepsy literature along with discussions with epilepsy patients served as sources for item derivation. A panel of experts reviewed the instrument for content validity. In phase two, testing of the instrument for reliability and validity was done using different groups of epilepsy patients. Reliability coefficients ranged from .81 for test-retest reliability to .93 for internal consistency. A strong positive correlation between self-efficacy and social support (r = .48, p less than .001) and between self-efficacy and self-management (r = .50, p less than .001) provided evidence to support the construct validity of the instrument.

Entities:  

Mesh:

Year:  1992        PMID: 1532014     DOI: 10.1097/01376517-199202000-00004

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  9 in total

1.  Differences in treatment-based beliefs and coping between African American and white men with prostate cancer.

Authors:  Colleen DiIorio; K Steenland; M Goodman; S Butler; J Liff; P Roberts
Journal:  J Community Health       Date:  2011-08

2.  Encouraging patients to self-care - the preliminary development and validation of the VeLUSET©, a self-efficacy tool for venous leg ulcer patients, aged 60 years and over.

Authors:  Annemarie Brown; Sally Kendall; Madeleine Flanagan; Michaela Cottee
Journal:  Int Wound J       Date:  2013-12-26       Impact factor: 3.315

3.  Individual, seizure-related, and psychosocial predictors of depressive symptoms among people with epilepsy over six months.

Authors:  Elizabeth L Reisinger; Colleen DiIorio
Journal:  Epilepsy Behav       Date:  2009-04-16       Impact factor: 2.937

4.  Self-management education for adults with poorly controlled epilepsy (SMILE (UK)): statistical, economic and qualitative analysis plan for a randomised controlled trial.

Authors:  Nicholas Magill; Leone Ridsdale; Laura H Goldstein; Paul McCrone; Myfanwy Morgan; Adam J Noble; Gus Baker; Mark Richardson; Stephanie Taylor; Sabine Landau
Journal:  Trials       Date:  2015-06-12       Impact factor: 2.279

5.  (Cost)-effectiveness of a multi-component intervention for adults with epilepsy: study protocol of a Dutch randomized controlled trial (ZMILE study).

Authors:  Loes Am Leenen; Ben Fm Wijnen; Reina Ja de Kinderen; Marian Hjm Majoie; Caroline M van Heugten; Silvia Maa Evers
Journal:  BMC Neurol       Date:  2014-12-24       Impact factor: 2.474

Review 6.  A systematic review and narrative synthesis of group self-management interventions for adults with epilepsy.

Authors:  Amelia Smith; Alison McKinlay; Gabriella Wojewodka; Leone Ridsdale
Journal:  BMC Neurol       Date:  2017-06-17       Impact factor: 2.474

7.  Clinic-Based Mobile Health Decision Support to Enhance Adult Epilepsy Self-Management: An Intervention Mapping Approach.

Authors:  Ross Shegog; Charles E Begley
Journal:  Front Public Health       Date:  2017-10-03

8.  A home-based, primary-care model for epilepsy care in India: Basis and design.

Authors:  Gagandeep Singh; Suman Sharma; Rajnder K Bansal; Raj K Setia; Sarit Sharma; Namita Bansal; Anuraag Chowdhury; Jatinder S Goraya; Susmita Chatterjee; Sukhpreet Kaur; Manpreet Kaur; Shivani Kalra; Josemir W Sander
Journal:  Epilepsia Open       Date:  2019-03-06

Review 9.  Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements.

Authors:  Annabel Nixon; Cicely Kerr; Katie Breheny; Diane Wild
Journal:  Health Qual Life Outcomes       Date:  2013-03-11       Impact factor: 3.186

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.